Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs

Epilepsy Research

Volumn 50, Issue 1-2, 2002, Pages 17-20

  Loscher W ^a   Leppik, I E ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adverse effects; Animal models; Drug resistance; Epilepsy; P glycoprotein; Progression

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

CONFERENCE PAPER; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; EPILEPSY; EUROPE; HUMAN; NEUROTOXICITY; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; REDUCTION; SEIZURE; SIDE EFFECT; UNITED STATES;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPILEPSY; HUMANS;

EID: 0036347770     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00064-5     Document Type: Conference Paper

References (0)